DataSheet_1_The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data.docx

ObjectiveThe purpose of this study was to evaluate the efficacy of denosumab treatment in patients with rheumatoid arthritis (RA).MethodsThe Medline, Embase and Cochrane Library databases were searched for relevant clinical studies. Studies that assessed the efficacy of denosumab in patients with RA were identified. The primary endpoints were the percent changes in bone mineral density (BMD), and the changes in modified total Sharp score (mTSS), modified Sharp erosion score and joint space narrowing (JSN) score. Pooled analyses were calculated using random-effect models.ResultsAfter searching the literature and performing further detailed assessments, 10 studies with a total of 1758 patients were included in the quantitative analysis. Pooled analyses showed that denosumab treatment significantly increased the percent changes in lumbar spine BMD [mean difference (MD): 5.12, confidence intervals (CI): 4.15 to 6.09], total hip BMD (MD: 2.72, 95% CI: 1.80 to 3.64) and femoral neck BMD (MD: 2.20, 95% CI: 0.94 to 3.46) compared with controls. Moreover, denosumab treatment significantly decreased the changes in mTSS (MD: -0.63, 95% CI: -0.86 to -0.41) and modified Sharp erosion score (MD: -0.62, 95% CI: -0.88 to -0.35). Subgroup analysis indicated that denosumab was superior to bisphosphonates for the improvement of BMD and the mitigation of joint destruction.ConclusionDenosumab treatment was associated with increased BMD and alleviated progression of joint destruction in RA patients, even when compared with bisphosphonates.</p

Synthetic Study toward the Misassigned (±)-Tronoharine

The synthesis of a pentacyclic indole compound corresponding to the core structure of the misassigned indole alkaloid, tronoharine (<b>1</b>), is presented. The key reactions were a formal [3 + 3] cycloaddition of an indol-2-yl carbinol with an azadiene for the construction of the 6/5/6/6 tetracyclic system containing an all-carbon quaternary center and an intramolecular substitution reaction of an amine and a triflate for the creation of the bridged azepine ring. In addition, some other interesting transformations discovered during the synthetic studies are also discussed

The MIC of tigecycline (TGC) in the multidrug resistant strains, with or without an efflux pump inhibitor, Carbonyl hydrogenated chlorophenyl hydrazone (CCCP).

<p>Footnote. MIC, minimum inhibitory concentration; TGC, tigecycline; CCCP, carbonyl cyanide chlorophenylhydrazone. ATCC 25922 was used as negative quality control strain.</p><p>The MIC of tigecycline (TGC) in the multidrug resistant strains, with or without an efflux pump inhibitor, Carbonyl hydrogenated chlorophenyl hydrazone (CCCP).</p

DataSheet_1_Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: A pilot study from a tertiary medical center.docx

BackgroundTo investigate the therapeutic effects and safety of low-dose and standard-dose rituximab (RTX) in the treatment of antiphospholipid syndrome (APS).MethodsIn this real-world study, we included 22 consecutive patients with APS who received RTX. Standard dose (SD) was defined as an overall dosage of RTX ≥ 1000mg in the induction period, and low dose (LD) was defined as an overall dosage of RTX ResultsOf included patients, 1 patients died, 2 patients withdrew and 19 patients completed 6-month follow-up. Nine patients received SD-RTX and 13 patients received LD-RTX, and elder patients [LD-RTX vs. SD-RTX: (49.1 ± 15.5) vs. (35.8 ± 12.3) years, p = 0.044] and patients with later-onset [LD-RTX vs. SD-RTX: (46.8 ± 16.3) vs. (31.3 ± 13.6) years, p = 0.029] were more frequently included in LD-RTX than SD-RTX. Following 6 month RTX treatment, 8 patients (42.1%) achieved complete remission, 8 patients (42.1%) achieved partial remission and 3 patients (15.8%) showed no remission. The titers of anticardiolipin antibodies [baseline vs. 6 months: 30.8 (10.7, 90) vs. 19.5 (2.45, 69.10) U/L, p = 0.023] and the levels of erythrocyte sedimentation rate [baseline vs. 6 months: 29 (6, 63) vs. '6 (3, 14) mm/h, p = 0.021] exhibited a significantly decrease in all APS patients. Remission rate and titers of anti-β2-glycoprotein I and lupus anticoagulant did not differ significantly between two groups.ConclusionRTX might be a safe and effective option for patients with APS, and low dose confers equal efficacy as standard dose. Further cohort studies are needed to confirm our findings.</p

Susceptibility profiles of nine tigecycline-resistant and one tigecycline-susceptible strain.

<p>Footnote. KB, Kirby-bauer; BMD, broth microdilution; MIC, minimum inhibitory concentration(test by BMD and E-test method) ; ATCC 25922 quality control strain KB value range from 20–27 cm, MIC range from 0.03–0.25 µg/mL.</p><p>Susceptibility profiles of nine tigecycline-resistant and one tigecycline-susceptible strain.</p

(a-k) Bar chart showing levels of pump genes and pump regulators in clinical strains of <i>K. pneumoniae</i>.

<p>Relative x-fold increases in the pump genes and regulator levels were quantified after comparisons with <i>K. pneumoniae</i> A111 (tigecycline-susceptible).</p

Additional file 12 of Integration of genetic, transcriptomic, and clinical data provides insight into 16p11.2 and 22q11.2 CNV genes

Additional file 12. Supplemental Acknowledgements. Members of the Psychiatric Genomics Consortium who contributed to this work

The characteristics and sources of the clinical isolates.

<p>Footnote. MLST, Multilocus sequence typing.</p><p>The characteristics and sources of the clinical isolates.</p

ALP activity of MC3T3 on the specimens after incubation for 7 days.

<p>The data are expressed as means±standard deviations (n = 3). One-way ANOVA followed by SNK post hoc test is utilized to determine the level of significance. *p<0.05 and **p<0.01.</p

Primers and fluorescent probes used for PCR.

<p>Footnotes. TaqMan probe labeled with an FAM dye at the 5′ end and a minor groove binder (MGB) and nonfluorescent quencher (NFQ) at the 3′ end.</p><p>Primers and fluorescent probes used for PCR.</p